The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano
October 31, 2018
(Length of interview: 11 minutes)
Tia Higano and Alicia Morgans share their perspective on the data analysis from the ERA-223 phase III study and highlight the value of incorporating bone health management, weight-bearing and resistance exercise when treating patients with prostate cancer.
Biographies:
Celestia (Tia) S. Higano, MD, Director, Prostate Cancer Clinical Research Group, Seattle Cancer Care Alliance and a prostate cancer specialist and Professor of Medicine at the University of Washington School of Medicine and a member of Fred Hutchinson Cancer Research Center.
Alicia Morgans, MD, MPH
Tia Higano and Alicia Morgans share their perspective on the data analysis from the ERA-223 phase III study and highlight the value of incorporating bone health management, weight-bearing and resistance exercise when treating patients with prostate cancer.
Biographies:
Celestia (Tia) S. Higano, MD, Director, Prostate Cancer Clinical Research Group, Seattle Cancer Care Alliance and a prostate cancer specialist and Professor of Medicine at the University of Washington School of Medicine and a member of Fred Hutchinson Cancer Research Center.
Alicia Morgans, MD, MPH
Related Content:
ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC
Watch: ERA 223: Presentation Summary from ESMO 2018 - Fred Saad
Watch an Interview with Fred Saad on: A Renewed Analysis of ERA 223
ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC
Watch: ERA 223: Presentation Summary from ESMO 2018 - Fred Saad
Watch an Interview with Fred Saad on: A Renewed Analysis of ERA 223